also called a Zepbound pen. The vial doses available are 2.5 mg and 5 mg, which is limited compared to the six Zepbound pen doses. Single-dose vials may be less convenient than an auto-injector pen.

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

the company has launched a single-dose 2.5 mg and 5 mg Zepbound vials in the U.S. exclusively through LillyDirect for less than half the list price of other incretin medicines for obesity.

On Tuesday, the agency gave the green light for Ozempic to help protect kidney function in people with diabetes and Zepbound as the first-ever drug treatment for sleep apnea in people with obesity.

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...